Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer.
Using a sandwich enzyme-linked immunoassay, plasma total cathepsin D concentration was assayed in 40 breast cancer patients and 84 patients with various liver diseases and compared to that of 52 normal subjects. There were no significant variations found in breast cancer patients related to tumor size, node invasiveness or metastases. In normal women, cathepsin D levels were slightly but not significantly increased in the luteal phase and in pregnancy. By contrast, plasma cathepsin D concentration was significantly increased in 70-75% of patients with liver disease (cirrhosis, hepatocarcinoma, hepatitis), but not in those with liver steatosis. Cathepsin D was independent of most of the plasma hepatic function tests and was correlated with alpha-fetoprotein in cirrhosis and with alpha-fucosidase in primary hepatocellular carcinoma. We conclude that plasma cathepsin D is not a useful marker in breast cancer. However, since the cellular level of this protease is associated with risk of metastasis in breast cancer, clinical follow-up will be required to test whether high cathepsin D plasma concentration has any prognostic value in liver cirrhosis and primary hepatocarcinoma.
Brouillet
J P
JP
Laboratoire de Biologie Cellulaire et Hormonale, CHRU Maternité, Montpellier, France.
Hanslick
B
B
Maudelonde
T
T
Pivat
M T
MT
Grenier
J
J
Blanc
F
F
Rochefort
H
H
D001943:Breast Neoplasms / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood*; D002402:Cathepsin D / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood*; D008113:Liver Neoplasms / Q000097:blood*; D011379:Prognosis
D002402:Cathepsin D